Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pharmacokinetics(PK), pharmacodynamics(PD) and immunogenicity of CM310 in children patients with moderate-to-severe atopic dermatitis.

Timeline

Start

2024-03-21

Primary completion

2025-01-23

Completion

2025-01-23

Publications

• Zhou C, Zhao Y, Zhu G, Wu L, Liu Y, Tao X, Zhao H, Wei Z, Lu W, Li W, Ding Y, Zhu X, Hu G, Cheng H, Xiao R, Man XY, Wang Q, Li S, Zeng T, Wang L, Xu Y, Zhang L, Liu W, Zhao G, Jia Y, Huang Y, Chen B, Zhang J. Efficacy and safety of stapokibart in adolescents with moderate-to-severe atopic dermatitis: a multicentre randomized double-blind placebo-controlled phase III trial. Br J Dermatol. 2026 May 19;194(6):1067-1076. doi: 10.1093/bjd/ljag052.

Drugs

Indications